2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N- methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3159-3173

  Walpole, C ^a,b   Ko, S Y ^a,c   Brown, M ^a,d   Beattie, D ^a   Campbell, E ^a   Dickenson, F ^a,e   Ewan, S ^a,e   Hughes, G A ^a   Lemaire, M ^a,f   Lerpiniere, J ^a   Patel, S ^a   Urban, L ^a  

^a Novatis Inst for Medical Sciences   (United Kingdom)

^b Astra Research Centre Montreal   (Canada)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^d DUPONT COMPANY   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROPHENYLCARBAMOYLPROLYL 3 (2 NAPHTHYL)ALANYL N BENZYL N METHYLAMIDE; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC INFLAMMATION; CHRONIC PAIN; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; ASPIRIN; BINDING, COMPETITIVE; BRAIN; DRUG DESIGN; GUINEA PIGS; HUMANS; HYPERALGESIA; KINETICS; MOLECULAR STRUCTURE; NAPHTHALENES; PAIN; PHENYLTHIOUREA; PROLINE; RABBITS; RATS; RECEPTORS, NEUROKININ-1; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15644373566     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970499g     Document Type: Article

References (40)

1. Nakanishi, S. Mammalian Tachykinin Receptors. Annu. Rev. Neurosci. 1991, 14, 123-136.
2. Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin Receptors and Tachykinin Receptor Antagonists J. Auton. Pharmacol. 1993, 13, 23-93.
3. 1) Receptor. Science 1991, 251, 435-437.
4. Garret, C.; Carruette, A.; Fardin, V.; Moussaoui, S.; Peyronel, J. F.; Blanchard, J. C.; Laduron, P. M. Pharmacological Properties of a Potent and Selective Nonpeptide Substance P Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10208-10212.
5. 2-[(4R)-Hydroxy-l-{(1-methyl-1-H-indol-3-yl)carbonyl]-L-prolyl]-N- methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds. J. Med. Chem. 1994, 37, 2090-2099.
6. 1 Antagonist. Eur. J. Pharmacol. 1993, 250, 403-413.
7. Schilling, W.; Bittiger, H.; Brugger, F.; Criscione, L.; Hauser, K.; Ofner, S.; Olpe, H.-R.; Vassout, A.; Veenstra, S. Approaches Towards the Design and Synthesis of Nonpeptidic Substance-P Antagonists. Perspectives in Medicinal Chemistry; Verlag Helvetica Chimica Acta: Basel, 1993; pp 207-220.
8. 1 Receptor Antagonists. J. Med. Chem. 1995, 38, 4793-4805.
9. Natsugari, H.; Ikeura, Y.; Kiyota, Y.; Ishimaru, T.; Saga, O.; Shirafuji, H.; Tanaka, T.; Kamo, I.; Doi, T.; Otsuka, M. Novel, Potent and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine. J. Med. Chem. 1995, 38, 3106-3120.
10. 1 Receptor Antagonists. J. Med. Chem. 1996, 39, 736-748.
11. McMahon, S. B.; Lewin, G. R.; Wall, P. D. Central hyperexcitability triggered by noxious inputs. Curr. Opin. Neurobiol. 1993, 3, 602-610.
12. 1 Neurokinin Receptor Activation and Enhanced A- and C-fiber Mediated Responses in the Rat Spinal Cord in vitro. J. Neurosci. 1994, 14, 3672-3687.
13. 1 Receptor Antagonist CP 99,994 in Models of Inflammatory and Neuropathic Pain in the Rat. Br. J. Pharmacol. 1995, 114, 350P.
14. 1 Receptor Antagonist Relieves Chronic Hyper-algesia in Diabetic Rats. Eur. J. Pharmacol. 1993, 241, 267-270.
15. Dionne, R. A.; Max, M. B.; Parada, S.; Gordon, S. M.; MacLean, D. B. Clin. Pharmacol. Ther. 1996, 59, 216.
16. Longmore, J.; Swain, C. J.; Hill R. G. Neurokinin receptors. Drug News Perspect. 1995, 8 (1), 5-23.
17. Kucharczyk N. Tachykinin antagonists in development. Exp. Opin. Invest. Drugs 1995, 4 (4), 299-311.
18. Elliott, J.; Seward, E. M. Neurokinin receptor antagonists. Exp. Opin. Ther. Pat. 1997, 7 (1), 43-54.
19. Ko, S. Y.; Lerpiniere, J.; Christofi, M. An Efficient Synthesis of Internal Guanidines. Synlett 1995, 8, 815.
20. 2-promoted Guanylation Reaction: The Scope and Limitations. Tetrahedron 1997, 53, 5291-5304.
21. 1) Receptor Antagonists in Models of Carrageenan and Substance P-induced Hyperalgesia in the Guinea Pig. Br. J. Pharmacol., in press.
22. 2 Receptors. J. Med. Chem. 1981, 24, 913-920.
23. 1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J. Biol. Chem. 1994, 269 (45), 28160-4.
24. 2 Receptor Histamine Antagonists. J. Med. Chem. 1988, 31, 656-71.
25. Gray, R. A.; Vander velde, D. G.; Burke, C. J.; Manning, M. C.; Middaugh, C. R.; Borchardt, R. T. Delta-Sleep-Inducing Peptide: Solution Conformational Studies of a Membrane-Permeable Peptide. Biochemistry. 1994, 33, 1323-1331.
26. Yamagami, C.; Takami, H.; Yamamoto, K.; Miyoshi, K.; Takao, N. Hydrophobic Properties of Anticonvulsant Phenylacetanilides. Relationships between Octanol-Water Partition Coefficient and Capacity Factor Determined by Reversed-Phase Liquid Chromatography. Chem. Pharm. Bull. 1984, 32, 4994-5002.
27. Urban, L.; Thomson, S. W. N.; Dray, A. Modulation of Spinal Excitability: Co-operation Between Neurokinins and Excitatory Amino Acid Neurotransmitters. Trends Neurosci. 1994, 17, 432-438.
28. Pardridge, W. M.; Eisenberg, J.; Cefalu, W. T. Absence of Albumin Receptor on Brain Capilliaries in vivo or in vitro. Am. J. Physiol. 1985, 249, E264-267.
29. Lin, T. H.; Lin, J. H. Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats. J. Pharmacol. Exp. Ther. 1990, 253, 45-50.
30. Lin, T. H.; Sawada, Y.; Sugiyama, T. Iga; Hanano, M. Inhibition of Blood-Brain Barrier Permeability of DL-propranolol by serum from acute renal failure rats. Biochem. Pharmacol. 1987, 36, 3425-3431.
31. Guillot, F.; Misslin, P.; LeMaire, M., Comparison of Fluvastatin and Lovastatin Blood-Brain Barrier Transfer using in vitro and in vivo Methods. J. Cardiovascular Pharmacology, 1993, 21, 339-346.
32. Private communication, Novartis Pharma Drug Metabolism and Pharmacokinetics department.
33. Private communication, Prof. F. Loor, Novartis Pharma, Basel, Switzerland.
34. 1 Receptor Antagonist. Br. J. Pharmacol. 1998, 124, 83-92.
35. Girard, G. R.; Hempel, J.; Hill, D, T.; Samenen, J.; Weinstock, J. Preparation of imidazolylalkanoates as angiotensin II antagonists. WO 9202510 A1 920220.
36. Masaaki, M.; Hagiwara, D.; Hiroshi, M. Preparation of acyldipeptide amides as tachykinin antagonists. Eur. Pat. Appl. EP 394989 A2 901031.
37. Handa, S.; Tanaka, Y.; Nishibata, A.; Inamoto, Y. Halogen-containing organic isocyanates. DE 2434055 750206.
38. Soo Y. Ko and Christopher Walpole, Tachykinin Antagonists, WO 96/18643 (June 20, 1996).
39. 3) receptor antagonists. 3. Ortho-substituted phenylureas. J. Med. Chem. 1990, 33, 1932-5.
40. Just, G.; Zamboni, R. β-Lactams II. The synthesis of cis-N-(2′-carboxyphenyl)-3-phenylacetamido-4-methoxymethyl-2-azetidinone. Can. J. Chem. 1978, 56 (21), 2720-4.